Allograft TNFβ and IL16 polymorphisms influence HCV recurrence and severity after liver transplantation

Liver Transplantation

Volumn 12, Issue 2, 2006, Pages 247-252

  Kimball, Pam ^a   Baker, Melissa ^a   Fisher, Robert A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 16; LYMPHOTOXIN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLOGRAFT; ARTICLE; CADAVER DONOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DNA POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; IN VITRO STUDY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT OUTCOME; ALLOTRANSPLANTATION; CELL CULTURE; COMPARATIVE STUDY; EPIDEMIOLOGY; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETICS; GRAFT REJECTION; HEPATITIS C VIRUS; HOSPITALIZATION; LIVER FAILURE; LIVER FUNCTION TEST; LYMPHOCYTE; MALE; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROBABILITY; RECURRENT DISEASE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VIROLOGY;

CELLS, CULTURED; FEMALE; GENETIC MARKERS; GENOTYPE; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-16; LIVER FAILURE; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; LYMPHOCYTES; LYMPHOTOXIN-ALPHA; MALE; POLYMORPHISM, GENETIC; PROBABILITY; RECURRENCE; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33244455882     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20611     Document Type: Article

References (25)

1. Forman L, Lewis J, Berlin J, Feldman H, Lucey M. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
2. Rosen H. Hepatitis C in the liver transplant recipient: current understanding and treatment. Microbes Infect 2002; 4:1253-1258.
3. Andus T, Holstege A. Role of cytokine in hepatic and hepatobiliary diseases. In: Aggarwal B, Puri R, eds. Human Cytokines: Their Role in Disease and Therapy. Cambridge: Blackwell Science, 1995:623-640.
4. Rosen H, McHutchison J, Conrad A, Lentz J, Marousek G, Rose S, et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002;97:714-720.
5. Yee L, Tang J, Herrera J, Kaslow R, Van Leeuwen D. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000;1:386-390.
6. Barrett S, Collins M, Kenny C, Ryan E, Keane C, Crowe J. Polymorphisms in tumor necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003;71:212-218.
7. Kimball P, Elswick R, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-α therapy. J Med Virol 2001;65:510-516.
8. Muller-Steinhardt M, Fricke L, Muller B, Ebel B, Kirchner H, Hartel C. Cooperative influence of the interleukin-6 promoter polymorphisms-597, -972 and -174 on long term kidney allograft survival. Am J Transplant 2004;4:402-406.
9. Mas V, Fisher RA, Maluf D, Archer K, Contos M, Mills S, et al. Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C viral disease in liver transplantation. Clin Genet 2004;65:191-201.
10. Glas J, Torok H, Unterhuber H, Radlmayr M, Flowaczny C. The -295T to C promoter polymorphism of the IL16 gene is associated with Crohn's disease. Clin Immunol 2003; 106:197-200.
11. Tambur A, Ortegel J, Ben-Ari Z, Shabtai E, Klein T, Michowiz R, et al. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation 2001;71:1475-1480.
12. Tsuchiay N, Tokushige K, Yamaguchi N, Hasegawa K, Hashimoto E, Yamauchi K, et al. Influence of TNF gene polymorphisms in patients with acute and fulminant hepatitis. J Gastroenterol 2004;39:859-866.
13. Fernandes H, Koneru B, Fernandes N, Hameed M, Cohen M, Raveche E, et al. Investigation of promoter polymorphisms in the tumor necrosis factor α and interleukin 10 genes in liver transplant patients. Transplantation 2002; 73:1886-1891.
14. De Oliveira J, Zavier P, Sampaio S, Tavares I, Mendes A. The synthesis by fine needle aspiration biopsy cultures of IL7, IL16 and IL18 is significantly associated with acute rejection in kidney transplants. Nephron 2002;92:622-628.
15. Jazrawi S, Zaman A, Muhammad Z, Rabkin J, Corless C, Olyaei A, et al. Tumor necrosis factor α promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs. Liver Transpl 2003;9:377-382.
16. Warle M, Farhan A, Metselaar H, Hop W, Perrey C, Zondervan P, et al. Cytokine gene polymorphisms and acute human liver graft rejection. Liver Transpl 2002;8:603-611.
17. Laan M, Linden A, Riise G. IL16 in the airways of lung allograft recipients with acute rejection or obliterative bronchiolitis. Clin Exp Immunol 2003;133:290-299.
18. Rosen H, Lentz J, Rose S, Rabkin J, Corless C, Taylor K, et al. Donor polymorphism of tumor necrosis factor gene. Transplantation 1999;68:1898-1902.
19. Lynch E, Heijens C, Horst N, Center D, Cruikshank W. IL16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol 2003;171:4965-4968.
20. Kaser A, Dunzendorfer S, Offner F, Ryan T, Schwabegger A, Cruikshank W, et al. A role for IL16 in the cross talk between dendritic cells and T cells. J Immunol 1999;163:3232-3238.
21. Cruikshank W, Kornfeld H, Center D. Interleukin 16. J Leukocyte Biol 2000;67:757-766.
22. Kimball P, McDougan-Reid F. TNFβ gene polymorphisms predict urinary tract infections following renal transplantation. Transplantation 2002;73:1110-1112.
23. Woitas R, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997;59:1012-1018.
24. Kimball P, Stravitz R. DR antigens influence graft outcome and HCV recurrence after liver transplantation. Transpl Proc 2005;37:1099-1100.
25. Zhou P, Devadas K, Tewari D, Jegorow A, Notkins A. Processing, secretion and anti-HIV-1 activity of IL16 with or without a signal peptide in CD4+ T cells. J Immunol 1999;163:906-912.